Formic Acid

Formic Acid

SCHEMBL3854971

CCCCC[CH]C(=O)O.O=CO.O=CO.O=CO.O=CO.O=CO.O=CO.O=CO.O=CO

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.47
TSHR P16473 1/20 0.46
PPARG P37231 4/20 0.45
TERT O14746 3/20 0.45
PTPN1 P18031 3/20 0.45
PPARD Q03181 3/20 0.45
PPARA Q07869 3/20 0.45
TOP1 P11387 3/20 0.45
MAPT P10636 2/20 0.45
BLM P54132 2/20 0.45
HSD17B10 Q99714 2/20 0.45
FABP4 P15090 2/20 0.45
GMNN O75496 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
APEX1 P27695 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL9849701 1.00 EP300 (0.47) EP300TSHRPPARGTERTPTPN1
Formic Acid SCHEMBL5026964 0.98 TSHR (0.50) EP300TSHRPPARGTERTPTPN1
Formic Acid SCHEMBL11035923 0.98 TSHR (0.50) EP300TSHRPPARGTERTPTPN1
Formic Acid SCHEMBL4249498 0.93 TSHR (0.46) EP300TSHRPPARGTERTPTPN1
Formic Acid SCHEMBL4256859 0.93 TSHR (0.46) EP300TSHRPPARGTERTPTPN1
SCHEMBL128509 0.93
SCHEMBL1276035 0.91 EP300 (0.56) EP300TSHRPPARGTERTPTPN1
SCHEMBL159834 0.91 EP300 (0.56) EP300TSHRPPARGTERTPTPN1
SCHEMBL241496 0.91 EP300 (0.56) EP300TSHRPPARGTERTPTPN1
SCHEMBL1275165 0.91 EP300 (0.56) EP300TSHRPPARGTERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582678-B2 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain D-PHARM LIMITED (IL) 2009-09-01 US disclosed
EP-1419129-B1 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN DPHARM LTD (IL) 2008-12-03 EP disclosed
EP-1419129-A4 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN DPHARM LTD (IL) 2006-05-10 EP disclosed
US-20040235949-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain D-PHARM LIMITED (IL) 2004-11-25 US disclosed
EP-1419129-A2 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN D-Pharm Limited (IL) 2004-05-19 EP disclosed
US-6518311-B2 Analgesics D-PHARM LTD. (IL) 2003-02-11 US disclosed
WO-2003000173-A2 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN D-PHARM LIMITED (IL) 2003-01-03 WO disclosed
US-20020042445-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain D-PHARM LTD. (IL) 2002-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235949-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain OPRL1, ELOVL5, ELOVL1 EP300 2610/4885TSHR 3438/4885PPARG 51/4885
US-20020042445-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain OPRL1, ELOVL5, ELOVL1 EP300 2610/4885TSHR 3438/4885PPARG 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.